The growing number of clinical trials in neuromuscular diseases and particularly in DMD and BMD, as well as the need for assessment of response to treatment, require new methodologies with highly-sensitive quantification of dystrophin [28]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.